http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005113290-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b0bb8bce91c3ee38410f52021f7eece |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2004-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8394e7bbedeea3640d2c5a9d54cd7531 |
| publicationDate | 2005-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005113290-A1 |
| titleOfInvention | Method and composition for treating cancer by converting soluble radioactive toxic agents into insoluble radioactive toxic precipitates via the action of non-mammalian enzymes bound to the non-endocytosing receptors of target cells |
| abstract | A method for the treatment of cancer is disclosed which is capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chemical agent. In accordance with the present invention, it was discovered that soluble precipitable materials can be made to accumulate as non-digestible precipitates in the extra-cellular fluid in the cancer region as a result of non-mammalian enzyme action. Precipitate accumulation is achieved by prior administration of a bispecific reagent with a non-mammalian enzyme moiety and a agent capable of binding to non-endocytosing receptors of target cancer cells. A soluble radioactive toxic therapeutic agent is then administered, the soluble toxic therapeutic agent being adapted to be converted by the non-mammalian enzyme moiety of the bound bispecific reagent into a new form which is retained adjacent to the target cancer cells for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells in the cancer region adjacent to the bispecific reagent. |
| priorityDate | 1997-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 419.